Navigation Links
Lantibio and TRB Chemedica Announce Licensing Agreement with Alcon for US Development and Marketing of Dry Eye Drug
Date:11/5/2007

chnology companies. For additional information about Paramount BioSciences, please visit http://www.paramountbio.com.

About TRB Chemedica

TRB Chemedica is a privately-owned Swiss pharmaceutical company with more than 20 years experience in research, development, manufacture and commercialization of innovative niche products in rheumatology, ophthalmology and neurology. TRB Chemedica has developed an expertise on the viscoelastic biopolymer, hyaluronic acid, manufacturing sterile finished products in its Swiss-based GMP facility. The company's product pipeline will help to fuel growth in each of the targeted therapeutic areas as well as introduce it into new areas of therapeutic focus. TRB Chemedica products are currently sold in more than 40 countries worldwide through wholly-owned subsidiaries, present in various countries in Europe, South America and Asia, and a growing network of licensing and distribution partners. For more information on TRB Chemedica visit the Company's web site at http://www.trbchemedica.com.

Caution Concerning Forward-Looking Statements. This press release might contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Lantibio's expectations and projections. Risks and uncertainties include success of clinical trials for Lantibio's products, intellectual property risks, need for additional financing or capital, ability to develop and successfully commercialize our products, ability to enter into licensing agreements, and the ability of the competition to render Lantibio's product candidates or technologies obsolete or noncompetitive. Lantibio assumes no obligation to updat
'/>"/>

SOURCE Lantibio, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... Sterlitech Corporation introduces ... comprehensive line of analytical laboratory equipment. With optimized features, such as PTFE-coated contact ... chemically resistant and maintenance-free solution for a broad range of vacuum filtration applications. ...
(Date:7/31/2015)... , July 31, 2015 In ... resources that help them drive positive health outcomes, ... vital source of patient care in their communities. ... annual tradeshow and conference, AmerisourceBergen announced a new ... Pharmacy Services Administration Organization and help independent pharmacies ...
(Date:7/31/2015)... ... 31, 2015 , ... Global Resorcinol Market 2015-2019 is a ... the global resorcinol industry. The report highlights the various growth prospects and the ... analysis of primary and secondary inputs from the existing players of the resorcinol ...
(Date:7/31/2015)... July 31, 2015 China Cord Blood Corporation ... leading provider of cord blood collection, laboratory ... services, today announced that the Company has filed its ... and Exchange Commission. The filed Form 20-F includes audited ... 2015. The Form 20-F can be accessed by visiting ...
Breaking Biology Technology:Sterlitech Launches New Line of Vacuum Pumps 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4China Cord Blood Corporation Files Its Annual Report on Form 20-F 2
... Research conducted at The,Walter and Eliza Hall ... licensing agreement signed between Australian biotechnology company,Bionomics, ... Under the Development and Licensing Agreement, Merck ... multiple sclerosis (MS) and other autoimmune,conditions. These ...
... -- WuXi PharmaTech (NYSE:,WX), a leading pharmaceutical, biotechnology ... operations in China and the United,States, today announced ... Vice President,of Human Resources., (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ... Mr. Zhu worked as Head of Asia Human,Resources ...
... Antonio (June 30, 2008) Researchers at The University of ... Infectious Diseases and The University of Texas Health Science Center ... to play a role in controlling the early infectious process ... agent that is the cause of tularemia. The findings will ...
Cached Biology Technology:MS Drug Development Agreement Based on WEHI's Medicinal Chemistry 2WuXi PharmaTech (NYSE: WX) Appoints Mr. Bob Zhu as VP of HR 2UTSA/UTHSCSA publish results on bio-threat agent 2
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the fourth quarter ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, ... ), the leading developer of human interface ... authentication technology, the industry,s first fully hardware ... innovative Match-in-Sensor secure authentication technology is literally ... pattern storage and biometric matching within the ...
(Date:7/8/2015)...  Trovagene, Inc. (NASDAQ: TROV ), a ... launch of a study that aims to determine ... technology for predicting response to treatment in advanced ... the novel immunotherapy agents Yervoy® (ipilumumab), a CTLA-4 ... 50-patient study will be led by researchers at ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... poisonous frog was recently discovered in a remote mountainous ... supported by the Conservation Leadership Programme (CLP). The new ... given the name the ?golden frog of Supat. ... to several other common species in the area. However, ...
... of highly organized epithelial cells line all the cavities ... the movement of liquids,and cells in the body organs. ... serve as a barrier against cancer, according to a,study ... week in,the online edition of the Proceedings of the ...
... today by the Health Department shed new light on the ... who responded to the World Trade Center disaster on September ... Health Registry, show that 3.6% of the 25,000 rescue and ... working at the site. That rate is 12 times what ...
Cached Biology News:Cells united against cancer 2Survey finds elevated rates of new asthma among WTC rescue and recovery workers 2Survey finds elevated rates of new asthma among WTC rescue and recovery workers 3